elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Empagliflozin
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Empagliflozin
RIS
0.001
(Research Intensity Score)
Papers
149
Top papers
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
2020 · 5146 citations
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
2020 · 891 citations
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
2024 · 105 citations
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
2024 · 87 citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 · 12115 citations
Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial
2023 · 70 citations
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial
2025 · 24 citations
Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes
2025 · 18 citations
Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors
2025 · 20 citations
Newest papers
SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes
2026
Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019–2023: a provider-level observational study
2026
Analysis of Allele-Specific Expression Highlights Novel Participants of Empagliflozin-Driven Effects on T2DM-Associated Regulatory Pathways
2026
Empagliflozin mitigated cisplatin induced renal endothelial dysfunction in rats via repressing oxidative, inflammatory, apoptotic and fibrotic signals
2026 · 1 citations
Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor
2026
Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment
2026 · 1 citations
Association between different sodium–glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis
2026
Inhibition of late sodium current prevents pathological hyperactivation of calcium/calmodulin‐dependent protein kinase IIδ in a murine model of acute doxorubicin‐related cardiotoxicity
2026
Sympathetic nervous system activity, tissue iron distribution, and their modulation by empagliflozin in the EMPATROPISM-FE trial
2026
Browse all papers →
Empagliflozin's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Empagliflozin's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link